Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
CRANBURY, N.J., June 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal. The underlying study was supported by grants from Palatin.
Michael A. Perelman, Ph.D., of the New York Presbyterian Hospital and the Weill Medical College of Cornell University, presented the poster on June 13, 2011 at the 20th World Congress for Sexual Health in Glasgow, United Kingdom. The paper, entitled "The Subjective Sexual Arousal Scale for Men (SSASM): Preliminary Development and Psychometric Validation of a Multidimensional Measure of Subjective Male Sexual Arousal," has been published in the online version of the Journal of Sexual Medicine and will appear in a forthcoming print issue. Stanley E. Althof, Ph.D., Executive Director of the Center for Marital and Sexual Health of South Florida and Emeritus Professor, Case Western Reserve University School of Medicine, and Raymond C. Rosen, Ph.D., of New England Research Institutes, are co-authors on the paper with Dr. Perelman.
The presentation and paper describe development and psychometric validation of a self-administered scale for assessing subjective male sexual arousal. Based upon recommendations of the Food and Drug Administration guidance on patient-reported outcome instruments, important aspects of male sexual arousal were identified through qualitative research of U.S. men with erectile dysfunction and healthy controls.
The Subjective Sexual Arousal Scale for Men (SSASM) may be useful in drug development for treatment of erectile dysfunction. The SSASM is the first validated research instrument with a focus on assessing subjective male sexual arousal in men with erectile dysfunction in a clinical trial setting.
Palatin supported the underlying research efforts as part of its commitment to developing novel drugs for treating sexual dysfunction, including both female sexual dysfunction and male erectile dysfunction.
Palatin Technologies, Inc. is developing subcutaneously administered bremelanotide for the treatment of female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies. An at-home Phase 2 clinical trial of subcutaneously administered bremelanotide for pre-menopausal women with female sexual dysfunction is scheduled to start in the current calendar quarter.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.
SOURCE Palatin Technologies, Inc.
Posted: June 2011